Please assess the completion status of the following clinical trial:

Trial Title: Anti-EGFR Immunoliposomes in Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven locally advanced or metastatic solid tumor.~2. ECOG Performance ≤ 2.~3. No additional standard therapy available for the patient.~4. EGFR overexpression (according to DAKO EGFR pharmDx - Test) determined in the most recently evaluable tumor tissue.~5. No concomitant anti-tumor therapy (steroids are permitted - in breast cancer and prostate cancer, steroid dose needs to remain stable during the study period).~6. At least four weeks since termination of any previous anti-tumor treatment (6 weeks in the case of nitrosoureas or mitomycin C).~7. In patients with previous anthracycline exposure, a normal echocardiogram (LVEF \> 50%) is required.~8. Age ≥ 18.~9. Male or female.~10. Female and male patients of reproductive age must be using effective contraception.~11. Willing and able to sign an informed consent prior to participation in the study and to comply with the protocol for the duration of the study.~Exclusion Criteria:~1. Pregnancy and/or breastfeeding.~2. Patients with the following laboratory values~   * neutrophils \< 1.5 x 109/L~  * platelets \< 100 x 109/L~  * serum creatine \> 3.0 x upper normal limit~  * ALAT, ASAT \> 3.0 x upper normal limit (5.0 x in patients with liver metastases as the only likely cause of enzyme alteration)~  * alkaline phosphatase \> 3.0 x upper normal limit (5.0 x in patients with liver or bone metastases as the only likely cause of enzyme alteration)~  * bilirubin \> 3.0 x upper normal limit~3. Participation in any investigational drug study within 4 weeks preceding treatment start.~4. Patients with clinically significant and uncontrolled renal- or hepatic disease.~5. Clinically significant cardiac disease: congestive heart failure (New York Heart Association class III or IV); symptomatic coronary artery disease; cardiac arrhythmia not well controlled with medication; myocardial infarction within the last 12 months.~6. Any serious underlying medical condition (at the judgement of the investigator) which could impair the ability of the patient to participate in the trial (e.g. active autoimmune disease, uncontrolled diabetes, etc.).~7. Any concomitant drugs contraindicated when administering Erbitux™ or Caelyx™ according to the Swissmedic-approved product information.~8. A cumulative doxorubicin dose of \> 300 mg/m2 BSA (or cardiotoxic anthracycline-equivalent).~9. Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent or interfering with compliance.~10. Brain metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anti-EGFR Immunoliposomes (Type: EXPERIMENTAL): anti-EGFR immunoliposomes loaded with doxorubicin. Dose escalating study. 3 patients per dose level. Dose levels: 5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete